Recent Updates
Recently added Catalysts

DESF

Phase 2

Allergic Reaction | Small molecule | Immunology |Aquestive Therapeutics, Inc.|Last Updated: Jul 15, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedCONTROLLEDDMC
Total Trials2
Total Enrollment68
FDA Designations
No designations recorded
Clinical trial landscape

DESF · 2 trials · 1 indication

Phase 2 1Phase 1 1
NCT06527937Pharmacokinetics Study of DESF in Adults With Oral Allergy SyndromeAllergic Reaction
COMPLETED36 Analytics
PHASE2COMPLETED
Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome
Allergic ReactionUnlock trial analytics
Study Endpoints
Primary Endpoints
Cmax
0 to 240 minutes post-dose

Baseline Corrected Maximum Epinephrine Plasma Concentration occurring at Tmax (Time to reach maximum concentration)

AUC0-10
0 to 10 minutes

Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 10 minutes

AUC0-20
0 to 20 minutes

Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 20 minutes

AUC0-30
0 to 30 minutes

Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 30 minutes

AUC0-45
0 to 45 minutes

Baseline Corrected Plasma Epinephrine Concentration-Time Curve from Time Zero to 45 minutes

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Single Doses of DESF and Intramuscular Manual InjectionEXPERIMENTALSingle dose of DESF (12 mg) administered after allergen challenge (Treatment Period 1), followed by a single dose of intramuscular (IM) manual injection (0.3 mg) without allergen challenge after a 24-hour washout period (Treatment Period 2), followed by a single dose of DESF (12 mg) without allergen challenge after a 14-day washout period from Treatment Period 1.
Repeat Doses of DESF and Intramuscular Manual InjectionEXPERIMENTALRepeat dose of DESF (24 mg \[12 mg x 2\]) administered after allergen challenge (Treatment Period 1), followed by a repeat dose of IM manual injection (0.6 mg \[0.3 mg x 2\]) without allergen challenge after a 24-hour washout period (Treatment Period 2), followed by a repeat dose of DESF (24 mg \[12 mg x 2\]) without allergen challenge after a 14-day washout period from Treatment Period 1.
Single Dose of DESFEXPERIMENTALA single dose (12 mg) of DESF administered.
Interventions
NameTypeDescription
DESFDRUGDESF administered in the sublingual space.
Epinephrine InjectionDRUGEpinephrine manual injection administered intramuscularly according to the approved prescribing information.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 55 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Willing and able to provide written informed consent and capable of following the protocol-required guidelines. * Healthy males and females 18 through 55 years of age. * Body weight ≥50 kg for males and ≥45 kg for females. * BMI ≥18 kg/m2 to ≤32 kg/m2. * Known history of oral ...

Countries:United StatesCanada
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJul 15, 2026NCT07703982NEW_TRIAL: changed
LOWJul 15, 2026NCT07703982NEW_TRIAL: changed